Developing a global understanding of the PRC and NuRD complexes in stem cell differentiation and in disease

Synonymous mutations frequently act as driver mutations in human cancers — Lehner and collaborator labs (2014)

Fran Supek, Belen Minana, Juan Valcarcel, Toni Gabaldon and Ben Lehner

Synonymous mutations change the sequence of a gene without directly altering the sequence of the encoded protein. Here, we present evidence that these "silent" mutations frequently contribute to human cancer. Selection on synonymous mutations in oncogenes is cancer-type specific, and although the functional consequences of cancer-associated synonymous mutations may be diverse, they recurrently alter exonic motifs that regulate splicing and are associated with changes in oncogene splicing in tumors. The p53 tumor suppressor (TP53) also has recurrent synonymous mutations, but, in contrast to those in oncogenes, these are adjacent to splice sites and inactivate them. 

We estimate that between one in two and one in five silent mutations in oncogenes have been selected, equating to approximately 6%- 8% of all selected single-nucleotide changes in these genes. In addition, our analyses suggest that dosage-sensitive oncogenes have selected mutations in their 3' UTRs.

Cell (2014) 6:132435  doi: 10.1016/j.cell.2014.01.051